Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
Zai Lab (ZLAB) Stock Price & Analysis
574 Followers
ZLAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.48 - $37.92
Previous Close$17.92
Volume878.62K
Average Volume (3M)650.29K
Market Cap
$1.79B
Enterprise Value$990.69M
Total Cash (Recent Filing)$820.41M
Total Debt (Recent Filing)$16.69M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 05, 2024EPS Estimate
-$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding99,208,743
10 Day Avg. Volume562,870
30 Day Avg. Volume650,286
Standard Deviation0.19
R-Squared0.09
Alpha-0.00291
Financial Highlights & Ratios
Price to Book (P/B)2.37
Price to Sales (P/S)28.40
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.77
Enterprise Value/Gross Profit7.03
Enterprise Value/Ebitda-3.40
Forecast
1Y Price Target
$51.33Price Target Upside186.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Zai Lab News
Bulls Say, Bears Say
Bulls Say
Commercial ProgressZai Lab's on-track commercialization progress is evidenced by the robust monthly sales performance of niraparib, highlighting strong market presence and product demand.
Drug ApprovalThe company's repotrectinib was approved by NMPA for ROS1-positive NSCLC in China.
Revenue GrowthProduct revenues for 1Q24 of $87.1M beat the company-provided consensus estimate of $76M and were up from $65.8M in 4Q23, driven by strong sales of Vyvgart, Nuzyra, and Optune.
Bears Say
Clinical Trial OutcomesThe study of efgartigimod on ITP did not meet the primary endpoint, resulting in the removal of revenue forecast for this indication from the model.
Market CompetitionThe expiration of key patents for olaparib has led to increased competition in China's PARP inhibitor market, necessitating a downward revision of niraparib's revenue forecast.
Regulatory ImpactSales for Optune were impacted by the anti-corruption campaign in China.
---
Ownership Overview
10.42% Insiders
20.24% Mutual Funds
19.16% Other Institutional Investors
50.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZLAB FAQ
What was Zai Lab’s price range in the past 12 months?
Zai Lab lowest stock price was $13.48 and its highest was $37.92 in the past 12 months.
What is Zai Lab’s market cap?
Currently, no data Available
When is Zai Lab’s upcoming earnings report date?
Zai Lab’s upcoming earnings report date is Aug 05, 2024 which is in 71 days.
How were Zai Lab’s earnings last quarter?
Zai Lab released its earnings results on May 08, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.925 by $0.375.
Is Zai Lab overvalued?
According to Wall Street analysts Zai Lab’s price is currently Undervalued.
Does Zai Lab pay dividends?
Zai Lab does not currently pay dividends.
What is Zai Lab’s EPS estimate?
Zai Lab’s EPS estimate is -$0.78.
How many shares outstanding does Zai Lab have?
Zai Lab has 99,208,740 shares outstanding.
What happened to Zai Lab’s price movement after its last earnings report?
Zai Lab reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.925. Following the earnings report the stock price went up 26.795%.
Which hedge fund is a major shareholder of Zai Lab?
Among the largest hedge funds holding Zai Lab’s share is Woodline Partners LP. It holds Zai Lab’s shares valued at 42M.
---
Zai Lab Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.33 (186.44% Upside)
$51.33 (186.44% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 270.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.02%
12-Months-Change
Fundamentals
Return on Equity
-38.44%
Trailing 12-Months
Asset Growth
-15.52%
Trailing 12-Months
Company Description
Zai Lab
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.
---
ZLAB Stock 12 Month Forecast
Average Price Target
$51.33
▲(186.44% Upside)
Technical Analysis
Best Analysts Covering ZLAB
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
+7.07%
reiterated a buy rating 3 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of +7.07% per trade.
---